The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference

BRAF mutations represent the main negative prognostic factor for metastatic colorectal cancer and a supposed negative predictive factor of response to standard chemotherapy. We have explored survival difference in right-sided colon cancer (RCC) patients according to BRAF mutations, with the aim to identify any predictive factors of response to targeted-based therapy. A retrospective study of RCC patients, with BRAF known mutation status, treated...